Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant

Acute Myeloid Leukemia Clinical Trial

Official title:

A Multicenter Phase II Trial of Inhibition of CD26 Peptidase Using Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults With Hematological Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01720264
• Other study ID #: 1208009261; HL112669
• Secondary ID: 1R01HL112669-01
• Status: Completed
• Phase: Phase 2
• Start date: November 2, 2012
• Est. completion date: December 15, 2017

Study information

• Verified date: December 2018
• Source: Indiana University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this trial is to assess the efficacy and safety of sitagliptin in enhancing engraftment following umbilical cord blood transplantation (recovery of blood counts after transplant).

Description:

Umbilical cord blood (UCB) is more commonly used for transplantation in children but is being used in adults more often. However, because adults are larger than children, the relatively smaller stem cell dose in UCB is major limitation for transplantation in adults and engraftment can be delayed. This study is trying to find out if the drug sitagliptin can be used to increase and speed up engraftment in adults receiving UCB transplantation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: December 15, 2017
• Est. primary completion date: August 27, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Patients must have one of the following disease types:

• Acute myeloid leukemia (AML) with disease features as described in the protocol.

• Acute lymphoblastic leukemia (ALL) with disease features as described in the protocol.

• Myelodysplasia with disease features as described in the protocol.

• Chronic myelogenous leukemia (CML) with disease features as described in the protocol.

• Patients with aggressive non-Hodgkin's lymphoma (NHL), including diffuse large cell lymphoma, mediastinal B-cell lymphoma, transformed lymphoma, mantle cell lymphoma, and peripheral T cell lymphoma, who also have one of the disease features as described in the protocol.

• At least 35 days following start of preceding leukemia induction cytotoxic chemotherapy.

• For patients in remission, there should be no readily available consenting HLA-matched related donor who is either matched fully matched or mismatched at only one locus of HLA-A, -B, and DRB1.

• No availability of a readily available HLA-matched volunteer unrelated donor (8 of 8 allele match at HLA-A, -B, -C and -DRB1).

• Patients must have a matched or partially matched UCB unit with >/= 2.5 x10^7 nucleated cells/kg of recipient weight at the time of cryopreservation.

• No current uncontrolled bacterial, viral or fungal infection (defined as currently taking medication and progression of clinical symptoms).

• No HIV disease.

• Non pregnant and non-nursing.

• Required baseline laboratory values as described in the protocol.

• Signed written informed consent.

Exclusion Criteria:

• Symptomatic uncontrolled coronary artery disease or congestive heart failure.

• Severe hypoxemia with room air PaO2<70, supplemental oxygen dependence, or DLCO<50% predicted.

• Patients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy.

• Prior allogeneic or autologous hematopoietic stem cell transplant in the last 6 months.

• Patients who are taking other insulin secretagogues and/or insulin.

• Patients who have hypersensitivity to sitagliptin.

• Patients with a history of pancreatitis, cholelithiasis, alcoholism, or fasting hypertriglyceridemia (> 2 x ULN).

Related Conditions & MeSH terms

• Acute Lymphoid Leukemia
• Acute Myeloid Leukemia
• Hematopoetic Myelodysplasia
• Leukemia
• Leukemia, Lymphoid
• Leukemia, Myelogenous, Chronic
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Lymphoma, Non-Hodgkin
• Myelodysplastic Syndromes
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Preleukemia

Intervention

Drug:
• Sitagliptin
Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.

Locations

Country	Name	City	State
United States	Indiana University Melvin and Bren Simon Cancer Center	Indianapolis	Indiana
United States	New York Medical College/Westchester Medical Center/Maria Fareri Children's Hosptial	Valhalla	New York

Sponsors (2)

Lead Sponsor	Collaborator
Sherif S. Farag	National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Percent of Subjects Engrafting by Day +30 After Transplantation	Percent of patients and the 95% Binomial Confidence interval who were able to achieve neutrophils engraftment (defined as the date of the first of three consecutive ANC values obtained on different days after transplantation during which the absolute neutrophils count (ANC) is at least 0.5 x109/l) by 30 days following transplant.	Day 0 to Day +30 post transplant
Secondary	Time to Neutrophil Engraftment	Time to neutrophil engraftment will be analyzed by the Kaplan-Meier method. The time to engraftment of neutrophils is defined as the time from day 0 to the date of the first of three consecutive days after transplantation during which the absolute neutrophils count (ANC) is at least 0.5 x109/l. Patients surviving at least 14 days after transplant will be evaluable for this endpoint. Patients who did not have neutrophil engraftment before death will be censored at the date of death. The median and 95% confidence intervals will be provided.	Transplant (Day 0) up to 1 year
Secondary	Time to Platelet Engraftment	Time to platelet engraftment will be analyzed by the Kaplan-Meier method. The time to engraftment of platelets is defined as the time from day 0 to the first of three consecutive Complete Blood Counts (CBCs) obtained on different days after transplantation during which the platelet count is at least 20 x109/l. The CBCs obtained should be at least seven days after the most recent platelet transfusion. Only patients who achieved engraftment of platelets will be included in the analysis. The median and 95% confidence intervals will be provided.	Transplant (Day 0) up to 1 year
Secondary	Number of Subjects With Treatment Related Adverse Events Grade 3 and 4 Non-hematological Toxicities	Number of unique patients who had a treatment related (possible, probable or definite) non-hematological adverse event that was graded 3 or greater.	Day 0 up to 3 years